Recent reviews and FDA-approved labeling of novel glucagon formulations (including ready-to-use liquid and nasal preparations) also reinforce the overall safety of glucagon analogues when used in low doses outside of traditional emergency indications [41]. Together, these preliminary findings suggest that MDG may represent a flexible and culturally compatible approach for managing mild hypoglycemia during fasting. This evidence concerns the gene GCG and Hypoglycemia.